Stock Events

Stock Events

Mersana Therapeutics 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0M4.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adc Therapeutics SA
ADCT
Mkt Cap151.36M
ADC Therapeutics develops ADCs targeting hematological malignancies and solid tumors, overlapping with Mersana's focus.
Macrogenics
MGNX
Mkt Cap290.48M
MacroGenics provides innovative antibody-based therapies for cancer, competing in the same biopharmaceutical space as Mersana.
Allogene Therapeutics
ALLO
Mkt Cap717.92M
Allogene Therapeutics works on allogeneic CAR T cell therapies, a different but competing approach in cancer treatment.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the oncology space with CAR T and other cancer therapies.
Novartis
NVS
Mkt Cap305.1B
Novartis offers a broad range of oncology treatments, including CAR T-cell therapies, competing across multiple areas with Mersana.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a diverse oncology portfolio, including ADCs, that competes with Mersana's therapeutic approaches.

About

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Martin H. Huber M.D.
Employees
102
Country
United States
ISIN
US59045L1061

Listings

MU
DE
0M4.MU
STU
DE
0M4.STU

0 Comments

Share your thoughts

FAQ

What is Mersana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Mersana Therapeutics stocks are traded under the ticker 0M4.STU.
How many employees does Mersana Therapeutics have?▼
As of July 09, 2026, the company has 102 employees.
In which sector is Mersana Therapeutics located?▼
Mersana Therapeutics operates in the Health & Wellness sector.
When did Mersana Therapeutics complete a stock split?▼
Mersana Therapeutics has not had any recent stock splits.
Where is Mersana Therapeutics headquartered?▼
Mersana Therapeutics is headquartered in Cambridge, United States.